In a phase I trial, one patient with SCLC who received PF562271 achieved SD for six or more cycles.58 Therefore, clinical trials testing FAK inhibitors in patients with SCLC should be conducted using splicing variants as biomarkers, and specific inhibitors for constitutively activated FAK6,7/FAK7 need to be developed for clinical testing. The gene discussed is PTK2; the disease is small cell lung carcinoma.